Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial

Group 1 - Brendan completed a Ph.D. in organic synthesis at Stanford University in 2009 and has a background in both pharmaceutical and biotech industries [1] - He worked for Merck from 2009 to 2013 and was involved in biotech startups such as Theravance and Aspira before joining Caltech [1] - Brendan is a co-founder and the first employee of 1200 Pharma, which received significant investment in the eight-figure range [1] - He remains an active investor with a focus on market trends, particularly in biotechnology stocks [1]